Background: Urinary excretion of alpha-1-microglobulin and beta-2-microglobulin reflects tubular damage and predicts outcome in patients with idiopathic membranous nephropathy with reasonable accuracy. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin are novel biomarkers of tubular damage. We investigated if these markers could improve prediction of outcome in idiopathic membranous nephropathy. Methods: We measured kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in urine samples from patients with idiopathic membranous nephropathy, who had nephrotic proteinuria and normal renal function. Excretion of alpha-1-microglobulin and beta-2-microglobulin had been measured previously. Progression was defined as a serum creatinine rise >30%, a rise in serum creatinine to an absolute value of 5135 mmol/L, or a clinical decision to start immunosuppressive therapy. Remission was defined as proteinuria <3.5 g/day and >50% reduction from baseline. Results: Sixty-nine patients were included. Median follow-up was 35 months (interquartile range 18-63 months). Progression occurred in 30 patients (44%), and spontaneous remission in 36 (52%). Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin excretion rates were significantly correlated with each other, and with alpha-1-microglobulin and beta-2-microglobulin. The areas under the receiver operating characteristic curves for progression were 0.75 (0.62-0.87) for kidney injury molecule-1 and 0.74 (0.62-0.87) for neutrophil gelatinase-associated lipocalin. In multivariate analysis with either alpha-1-microglobulin and beta-2-microglobulin, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin did not independently predict outcome. Conclusion: Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin excretion rates correlated with excretion rates of other tubular damage markers and predicted outcome in patients with idiopathic membranous nephropathy. They did not add prognostic value compared to measurement of either alpha-1-microglobulin or beta-2-microglobulin.
Background
Idiopathic membranous nephropathy (iMN) is a leading cause of nephrotic syndrome in Caucasian adults. 1 Natural history studies with follow-up of at least three years indicate that approximately 50% of patients with nephrotic iMN develop renal failure. [2] [3] [4] It has been demonstrated that a restrictive treatment strategy which limits immunosuppressive treatment to patients with established renal insufficiency results in good longterm renal survival. 5, 6 Although this strategy assures that patients who will develop spontaneous remission do not unnecessarily receive toxic therapy, it delays its use in others. 7 Preferably, immunosuppressive treatment should be initiated at an early stage and only in patients who will otherwise develop progressive disease. This requires a highly accurate method to identify highrisk patients.
High urinary concentrations of proteins that reflect tubular or glomerular damage precede a decline in estimated glomerular filtration rate (eGFR) in patients with iMN. [8] [9] [10] [11] We have previously validated a prognostic model to predict disease progression in patients with iMN and preserved renal function using urinary beta-2microglobulin (b2m) and IgG excretion rates. 12 However, a recent evaluation of the data indicated that a substantial proportion of patients are still misclassified when urinary b2 m or the closely resembling biomarker alpha-1-microglobulin (a1m), or IgG are used as predictors. 3 Kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are novel and early markers of tubular damage, which have mainly been studied in the context of acute kidney injury. [13] [14] [15] [16] There is increasing evidence for a prognostic value of KIM-1 and NGAL in patients with glomerular disease. [17] [18] [19] [20] Neither were strongly correlated with b2 m excretion in proteinuric patients with IgA nephropathy. 17 The aim of the study was to evaluate the prognostic value of urinary KIM-1 and NGAL excretion in patients with iMN.
Methods Subjects
The present study cohort represents a subgroup from a previously described cohort of 129 patients with biopsy-proven iMN designed to re-evaluate the prognostic value of urinary low-molecular weight proteins a1m and b2m. 3 Patients who were referred to our clinic for a timed urinary protein measurement between 1995 and 2009 had been included. Other inclusion criteria were preserved renal function (defined by a serum creatinine <135 mmol/L), proteinuria 53.0 g/10 mmol creatinine, and absence of prior immunosuppressive therapy. Patients were excluded if follow-up was <1 year, or if time between renal biopsy and measurement was >3 years. In the present study, we included all patients from this cohort who had available stored urine samples for measurement of KIM-1 and NGAL. Patients were followed until a predefined end point (see below) was reached or until June 2011.
Methods
Patients with iMN were evaluated using a standardized protocol, which included a timed measurement of urinary proteins including b2m and a1m. 12 Patients were instructed to take sodium bicarbonate on the night before urinary measurement to obtain a urinary pH >6.0, which is mandatory for reliable measurement of b2 m. Timed urine samples were collected, and blood samples were obtained. Urinary b2 m was measured by an in-house developed ELISA (detection limit of 0.002 mg/L, interassay variation coefficient of 5.7%), and urinary a1 m was measured by immunonephelometry on a BNII nephelometer (Behring, Marburg, Germany; detection limit for urinary a1m was 2 mg/L, and interassay variation coefficient was 4.7%). 12, 21 A portion of the timed urine sample was immediately centrifuged (10 min, 3000 r/min) and stored at À80 C. Urinary KIM-1 and NGAL concentrations were measured after overnight thawing of frozen stored samples using human-specific ELISA (intra-assay and inter-assay variation coefficients for KIM-1 7.4 and 14.5%; for NGAL 6.8 and 19.6%). Antibodies were obtained from R&D systems (Minneapolis, MN). Detection limit for KIM-1 was 0.02 mg/L, for NGAL 0.66 mg/L. All measurements were performed in duplicate.
Outcome
Progression was defined as (a) a 530% rise in serum creatinine, (b) a rise in serum creatinine to an absolute value 5135 mmol/L, or (c) other clinical indications for starting immunosuppressive therapy established by the treating nephrologist. Complete remission was defined as proteinuria reduction to <0.2 g/10 mmol creatinine. Partial remission was defined as proteinuria <3.5 g/10 mmol creatinine with reduction of >50% from baseline in the presence of stable renal function. 22 
Statistical analyses
Median values and interquartile range are reported for non-normally distributed values. Statistical differences between groups were assessed with 2 or Mann-Whitney U test. Correlations between parameters were calculated with Spearman's correlation coefficient. Areas under the receiver operating characteristic curves (ROC-AUC) were used to assess prognostic performance of respective biomarkers. For all biomarkers, the optimal cut-off level was determined where the most patients were correctly classified. The discriminatory capacity for progression and remission of respective biomarkers at optimal cut-off levels was compared using the net reclassification improvement (NRI). Calibration of biomarkers was plotted using the Hosmer-Lemeshow goodness-of-fit test, which compares expected versus observed progression across deciles of risk. We used logistic regression models to evaluate combinations of biomarkers. Statistical analyses were performed with SPSS (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.) and GraphPad Prism (GraphPad Prism version 5.03 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com). P values <0.05 were considered to reflect statistical significance.
Results
From the described cohort of 129 patients with iMN included in the prognostic study of urinary a1m and b2m, 69 (53%) had available stored urine samples for measurement of KIM-1 and NGAL. 3 Four patients had missing values for b2m because urinary pH was below 6.0 (b2m is unstable at these pH levels). Two of these patients developed progressive disease. The large majority (96%) of patients reached an end point during follow-up ( Table 1 ).
Excretion of KIM-1 and NGAL
KIM-1 excretion was 1.7 ng/min (IQR 0.3-3.4 ng/min) and NGAL excretion was 17.8 ng/min (IQR 11.0-57.2 ng/min) during timed urinary measurement. For comparison, median KIM-1 excretion was 0.6 (IQR 0.4-0.9 ng/min), and median NGAL excretion was 15.6 ng/min (IQR 10.4-19.9 ng/min) in 65 healthy adult controls. 17 Excretion rates of both KIM-1 and NGAL correlated significantly with each other, and excretion rates of a1m and b2m (Table 2) . Furthermore, excretion rates of KIM-1 and NGAL correlated significantly with proteinuria and eGFR ( Table 2 ).
Prediction of outcome
ROC curves for progression and remission, and optimal cut-off values of respective biomarkers are shown in Figure 1 and Table 3 . The NRI values show that there is no significant improvement in outcome prediction of KIM-1 or NGAL compared to a1m or b2m ( Figure 2 ). Hosmer-Lemeshow goodness-of-fit tests were non-significant for all biomarkers, indicating good model calibration ( Supplementary Figure) . In the backward stepwise logistic regression models, KIM-1 and NGAL did not reach statistical significance as independent predictors.
Reclassifications using KIM-1 and NGAL in patients misclassified by b2m
Prognostic misclassifications by b2m cut-off levels were studied in detail in order to detect a potential benefit of KIM-1 and NGAL in certain subgroups. Seven patients with b2m < 1.0 mg/min progressed ( Supplementary Table) . A common characteristic in most of these patients was performance of urinary measurement relatively early after biopsy. Three patients were reclassified using KIM-1 and two by NGAL prognostic cut-off levels as described above. Nine patients with b2m 5 1.0 mg/min did not progress ( Supplementary Table) , and all reached remissions. Four of them were correctly reclassified with NGAL and three by KIM-1 using the described cut-off values.
Discussion
Our study clearly demonstrates that the recently identified urinary biomarkers NGAL and KIM-1 predict outcome in patients with iMN and preserved renal function. However, overall they did not have additional prognostic value beyond established markers a1m and b2m.
NGAL is a low-molecular weight protein of $25 kDa. It is expressed on neutrophils and also on inflamed epithelia including kidney tubules. 23, 24 In experimental acute kidney injury, tubular NGAL expression and urinary NGAL excretion occur within 2 h, before b2m is observed in the urine. 24 Increased urinary NGAL excretion is also observed in glomerular disease. A strong correlation between proximal tubular NGAL expression and urinary NGAL has been found in patients with IgA nephropathy, suggesting that tubular cells actively produce NGAL. 25 KIM-1 is a transmembrane glycoprotein, which is not expressed in the normal kidney. It is strongly upregulated by proximal tubular epithelial cells after toxic or ischemic acute kidney injury. 26 Cleavage of KIM-1 by MAP-kinases results in urinary excretion of its 90 kDa soluble ectodomain. 27 There is a strong relationship between tubular expression and urinary excretion of KIM-1. 28 It is not produced by other cells to an Table 3 . Receiver under the operating characteristic curves of urinary biomarkers for progression and remission of idiopathic membranous nephropathy and optimal prognostic cut-off levels. 50 mg/min), respectively. Urinary b2m was measured in 65 patients. (a) KIM-1 versus b2m. NRI progression 3.5% (95% CI À12.1 to 19.5%); NRI remission À8.6% (95% CI À23.4 to 6.2%); overall NRI À5.0% (95% CI À26.7 to 16.6%). (b) NGAL versus b2m. NRI progression À10.7% (95% CI À31 to 9.1%); NRI remission 8.6% (95% CI À4.0 to 21.1%); overall NRI À2.1% (95% CI À24.5 to 20.2%).
(c) KIM-1 versus a1m. NRI progression 10.0% (95% CI À7.3 to 27.3%); NRI remission À13.9% (95% CI À31.9 to 4.2%); overall NRI À3.9% (95% CI À28.9 to 21.1%). (d) NGAL versus a1m. NRI progression 3.3% (95% CI À11.2 to 17.9%); NRI remission 0 (À16.0 to 16.0%); overall NRI 3.3% (95% CI À17.5 to 24.1%).
extent that can account for urinary levels that are observed in patients with kidney disease. 29 Thus, urinary NGAL and KIM-1 are specific markers of tubular cell injury. In contrast, the low-molecular weight proteins a1m and b2m only reflect a reduction in tubular reabsorptive capacity. We hypothesized that KIM-1 and NGAL may be more specific markers of tubular injury and thus better predictors of outcome than a1m and b2m. Evidently, neither KIM-1 nor NGAL showed improved overall prognostic accuracy. By contrast, we have identified KIM-1 as an independent predictor of ESRD in IgA nephropathy, where a1m and b2m did not predict outcome. 17 There were strong significant correlations between the excretion rates of respective proteins in iMN, which were absent in IgA nephropathy. Tubular dysfunction may progress faster in the heavily nephrotic patients with iMN. We hypothesize that elevated NGAL and/or KIM-1 may have preceded elevated a1m and b2m in patients with progressive iMN. The data of patients with progression in the presence of b2m below prognostic cut-off support this hypothesis. Indeed, urinary measurement was performed shortly after biopsy in most of these patients. Thus, KIM-1 and NGAL may have added prognostic value in the earliest stages of iMN.
The definition for progression used in our study may be criticized. Assuming an initial normal kidney function, a rise to a serum creatinine 5135 mmol/L indicates a serious deterioration which is associated with progression to ESRD. 5, 30 The other criteria for progression are in conformity with current guidelines for treatment of iMN. 31 The present cohort comprises a subgroup from a larger study that was conducted to evaluate prognostic accuracy of urinary a1m and b2m in iMN. 3 Although optimal prognostic cut-off values of urinary a1m and b2m were unchanged in this subgroup, the smaller number of patients limits the accuracy of the estimated predictive values of KIM-1 and NGAL excretion.
In conclusion, we have shown that urinary KIM-1 and NGAL are elevated in many patients with nephrotic iMN and preserved renal function. However, KIM-1 and NGAL measurement did not improve prognostic accuracy when compared or combined with established markers. Our data suggest that these markers may have added value in the earliest stages of the disease. Additional studies with longitudinal followup of these urinary markers are warranted to investigate their potential benefit in iMN.
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